This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Sublingual Immunotherapy on Grasspollen Allergy

This study has been completed.
Information provided by:
Radboud University Identifier:
First received: September 7, 2005
Last updated: NA
Last verified: November 2003
History: No changes posted
The objective of the study is to document the objective immunological effects of SLIT on the nasal mucosa. Better understanding of these immunological pathways, in which this widely practised clinical therapy is likely to work, can only benefit the overall outcome of this, more patient friendly, therapy and it will demonstrate the effects of SLIT on the allergic reaction, with objective parameters, in the nasal tissues showing it to be a true etiological treatment of allergy.

Condition Intervention Phase
Hayfever Drug: Oralgen Procedure: Nasal biopsy Procedure: Nasal washing Procedure: Peak nasal inspiratory flow Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Placebo Controlled, Double-Blind, Randomised Study to Assess Efficacy of Sublingual Immunotherapy in Patients With Grass Pollen Allergy Through Assessment of Its Immunological Effects on the Mucosal Tissue of the Nose.

Resource links provided by NLM:

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Double blind placebo controlled evaluation of the immunological effects of SLIT on the nasal mucosal tissue of adult humans with sever

Secondary Outcome Measures:
  • I. Correlating immunological effects to a retrospective subjective complaint reduction.
  • II. Rescue medication decrease through SLIT.
  • III. Determining the effects of SLIT on decongestion.
  • IV. Assessment of treatment compliance.

Estimated Enrollment: 38
Study Start Date: January 2002
Estimated Study Completion Date: December 2006
Detailed Description:
Double blind placebo controlled evaluation of the immunological effects (decrease of IgE specific cells and the decrease of Th2 mediator release, respectively increase of Th1 mediator release) of SLIT on the nasal mucosal tissue of adult humans with severe rhinocunjunctivitis due to grass pollen allergy.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age 18 and older.
  2. Patients known in general practice with documented clinical history of grass pollen allergy with moderate disease intensity as retrospectively derived from the use of symptomatic allergy medication during the previous grass pollen season, i.e. regular use of cromoglycates as nasal spray and/or eye drops, and/or regular use of anti histamine tablets or sprays and/or limited use of local acting or systemically administered corticosteroids.
  3. Positive (ARTU) grass pollen specific skin prick test (despite negative RAST).

Exclusion Criteria:

  1. Clinical history of severe asthmatic symptoms requiring inhalant therapy with daily pulmonary steroids during at least 3 months a year.
  2. Symptomatic perennial allergic rhinitis. Meaning perennial allergy is allowed if the allergen is not present in patients' daily life (especially one month prior to provocation) and if they have no apparent symptoms of this perennial allergy.
  3. Other seasonal allergic rhinitis are not allowed unless it is asymptomatic during the period of provocation.
  4. The intention to subject the patient to surgery of the nasal cavity in the course of the study.
  5. Previous immunotherapy.
  6. Negative (ARTU) grass pollen specific skin prick test (despite positive RAST).
  7. Contraindications to sublingual immunotherapy, i.e.:

    • Malignancies and serious disorders of the oral cavity
    • History of status asthmaticus and anaphylactic shock
    • Aggressively developing asthmatic symptoms
    • Serious chronic inflammations, chronic disorders associated with fever, particularly of the bronchial tubes
    • Irreversible, secondary changes in reactive organs (emphysema, bronchiectasis)
    • Auto immune diseases and immunodeficiency
    • Concurrent therapy involving immunosuppressives
    • Systemic and collagen diseases
    • Tuberculosis of the lung and tuberculosis
    • Serious psychological disorders
    • Documented hypersensitivity to glycerol
    • Pregnancy
    • Serious cardiovascular disease
    • Usage of b -blockers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00150514

Radboud university hospital
Nijmegen, Gelderland, Netherlands, 6500
Sponsors and Collaborators
Radboud University
Study Chair: K Ingels, MD Radboud University
  More Information Identifier: NCT00150514     History of Changes
Other Study ID Numbers: AB0103
Study First Received: September 7, 2005
Last Updated: September 7, 2005

Keywords provided by Radboud University:
nasal biopsy grasspollen sublingual immunotherapy processed this record on August 18, 2017